Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.56 |
| ▸ | PKM | P14618 | 12/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23115307 | 0.96 | DDB1 (0.54) | DDB1CRBNPKMMAPTMEN1 | |
| SCHEMBL23116695 | 0.88 | PKM (0.44) | DDB1CRBNPKMMAPTMEN1 | |
| SCHEMBL23115309 | 0.86 | PKM (0.49) | DDB1CRBNPKMMAPTMEN1 | |
| SCHEMBL23116697 | 0.86 | DDB1 (0.55) | DDB1CRBNPKM | |
| SCHEMBL23116696 | 0.86 | PKM (0.45) | DDB1CRBNPKMMAPTMEN1 | |
| SCHEMBL23115317 | 0.84 | PKM (0.52) | DDB1CRBNPKMMAPTMEN1 | |
| SCHEMBL23115299 | 0.84 | PKM (0.52) | DDB1CRBNPKMMAPTTP53 | |
| SCHEMBL23115180 | 0.84 | DDB1 (0.56) | DDB1CRBNPKMMAPTMEN1 | |
| SCHEMBL23115314 | 0.83 | PKM (0.49) | DDB1CRBNPKMMAPTMEN1 | |
| SCHEMBL23115322 | 0.82 | DDB1 (0.43) | DDB1CRBNPKMMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| WO-2021047674-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | 南京明德新药研发有限公司 | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | CRBN, CRKL, NCOR1 | DDB1 1432/4885CRBN 1/4885PKM 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.